Four Weeks of Antibiotics better than 2 weeks course in Kids with Chronic Wet Cough

Written By :  MD Bureau
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-05-28 02:15 GMT   |   Update On 2021-05-28 04:26 GMT
Advertisement

Protracted bacterial bronchitis (PBB) is a leading cause of chronic wet cough in children. In a recent study, researchers have found that four weeks of amoxicillin-clavulanate is better than 2 weeks regimen in treating chronic wet cough in children. The study findings were published in THE LANCET Respiratory Medicine on May 25, 2021.

The current standard treatment in European and American guidelines is 2 weeks of antibiotics, but the optimal duration of therapy is unknown. Therefore, Dr Tom J C Ruffles and his team conducted a first randomized controlled trial to assess the duration of antibiotic treatment in children with chronic wet cough and suspected PBB. The researchers hypothesized that 4 weeks of amoxicillin-clavulanate is superior to 2 weeks for improving clinical outcomes.

Advertisement

It was a multicenter, parallel, double-blind, placebo-controlled, randomized controlled trial. The researchers included a total of 106 children with chronic (>4 weeks duration) wet cough and suspected PBB. They were randomly assigned to receive 4 weeks of amoxicillin-clavulanate (25–35 mg/kg twice daily oral suspension; 4-week group n=52) or 2 weeks of amoxicillin-clavulanate followed by 2 weeks of placebo (2-week group n=54). The major outcome assessed was a clinical cure (cough resolution) by day 28. The researchers also assessed the recurrence of PBB at 6 months, time to next exacerbation, change in Parent-proxy Cough-Specific Quality-of-Life (PC-QoL) score from baseline to day 28 and from day 28 to 7 months, adverse events, nasal swab bacteriology, and antimicrobial resistance.

Key findings of the study were:

  • By day 28, the researchers found that the primary endpoint of clinical cure in the 4-week group (32 [62%] of 52 patients) was not significantly different to the 2-week group (38 [70%] of 54 patients; adjusted relative risk 0·87.).
  • They noted that the time to next wet cough exacerbation was significantly longer in the 4-week group than the 2-week group (median 150 days vs 36 days; adjusted hazard ratio 0·47).
  • They also noted that the rate of recurrence of PBB at six months was 53% in the 4-week group and 74% in the 2-week group. However, they found no significant difference between the groups (adjusted odds ratio 0·39).
  • They observed a significant improvement in the PC-QoL from baseline to day 28 in both groups, but they found no significant difference between them (mean difference in change −0·2).
  • The median PC-QOL and the data on respiratory pathogens and antimicrobial resistance were similar between groups.
  • They reported 13 adverse events (25%) in the 2-week group and ten (19%) in the 4-week group.

The authors concluded, "A 4-week course of amoxicillin-clavulanate for treating children with chronic wet cough and suspected PBB confers little advantage compared with a 2-week course in achieving clinical cure by 28 days. However, as a 4-week duration led to a longer cough-free period, identifying children who would benefit from a longer antibiotic course is a priority."

For further Information:

DOI: https://doi.org/10.1016/S2213-2600(21)00104-1


Tags:    
Article Source :   THE LANCET Respiratory Medicine 

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News